Drug intelligence / Profile preview

HA-22-31

Development stage: Preclinical
Lead developer: Saskatchewan Cancer Agency
Modality: Small Molecules

Overview

HA-22-31 is a small molecule inhibitor of chloride intracellular channel 3 (CLIC3) currently in preclinical development for the treatment of metastatic breast cancer. CLIC3 is secreted by cancer cells and cancer-associated fibroblasts, promoting tumor invasion and angiogenesis through its oxidoreductase activity, which inhibits transglutaminase-2 (TGM2). HA-22-31 was identified via an in silico screen of over 10 million small molecules and subsequent structure-activity relationship (SAR) analysis. It directly binds to CLIC3 with an IC50 of 1.7 μM, significantly inhibiting cell migration and tumor metastasis in preclinical models.

Targets

CLIC3 (Chloride intracellular channel protein 3)

Beyond the preview

Go deeper on HA-22-31.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HA-22-31.

Explore the full profile